Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...

Lilly reports Phase 3 data showing retatrutide delivered substantial weight loss, reduced knee pain, and improved ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly (NYSE:LLY) stock rose 3% in premarket trading Thursday after the company’s experimental triple agonist drug retatrutide showed impressive weight loss results and significant osteoarthritis ...

Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...